Mesa Laboratories, Inc. Form 10-Q Summary
Reporting period: The provided filing is for the three and nine months ended December 31, 2022, Mesa’s fiscal 2023 third quarter and year-to-date period. The request metadata identifies “2021 Q3,” but the filing text clearly reports fiscal 2023 results. Amounts are in thousands except per-share data.
Business Context
Mesa manufactures and sells life science tools and critical quality-control products and services through four reportable divisions: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The company operates in the United States and Europe and sells globally through direct sales and distributors.
Key Financial Metrics
| Metric | Three Months Ended Dec. 31, 2022 | Three Months Ended Dec. 31, 2021 | Nine Months Ended Dec. 31, 2022 | Nine Months Ended Dec. 31, 2021 |
|---|---|---|---|---|
| Revenue | $54,287 | $54,696 | $163,489 | $125,456 |
| Gross profit | $32,765 | $28,627 | $100,492 | $73,978 |
| Gross margin | 60.3% | 52.3% | 61.5% | 59.0% |
| Operating income (loss) | $3,402 | $(2,512) | $2,803 | $4,812 |
| Net income (loss) | $451 | $(2,060) | $319 | $3,655 |
| Diluted EPS | $0.08 | $(0.39) | $0.06 | $0.69 |
| Cash flow from operations | Not provided for the quarter | Not provided for the quarter | $15,464 | $29,921 |
Balance sheet at December 31, 2022: Cash and equivalents were $26,101; working capital was $72,568; total assets were $662,984; and total stockholders’ equity was $387,205. Inventories were $33,739, up from $24,606 at March 31, 2022.
Debt and liquidity: The company had $19,000 outstanding under its revolving Credit Facility and $172,500 principal amount of 1.375% convertible senior notes due August 15, 2025, with a net carrying value of $170,044. The Credit Facility matures in March 2025, and Mesa was in compliance with all financial covenants. The company also has capacity under a $150,000 open-market equity sale agreement.
Cash flow and capital allocation: Year-to-date investing cash outflow was $8,468, including $4,950 for the Belyntic acquisition and $3,518 for capital expenditures. Financing cash outflow was $28,936, primarily reflecting $30,000 of Credit Facility repayments, $2,550 of dividends, and $4,523 of proceeds from stock-option exercises. Cash declined by $23,245 from March 31, 2022.
Material Changes Versus Prior Comparable Period
- Third-quarter revenue declined 1%, while nine-month revenue increased 30%, primarily because the prior-year nine-month period included only a partial contribution from the Agena acquisition completed October 20, 2021.
- Organic revenue declined 2.1% in the quarter and increased 3.5% year to date. Foreign exchange headwinds and lower COVID-related revenue affected the quarter.
- Gross margin improved to 60.3% in the quarter from 52.3%, and to 61.5% year to date from 59.0%. The prior-year comparison was depressed by a $6,062 non-cash inventory step-up charge associated with Agena purchase accounting.
- Operating income improved to $3,402 in the quarter from an operating loss of $2,512, but declined to $2,803 year to date from $4,812 because of higher operating expenses following the Agena acquisition.
- Net income improved to $451 in the quarter from a loss of $2,060, but declined to $319 year to date from $3,655. The year-to-date effective tax rate was unusually high at 384.8%, compared with a benefit rate of 1.0% in the prior-year period.
- Operating cash flow fell to $15,464 from $29,921, primarily because working capital consumed more cash, including a $9,191 increase in inventory.
- Clinical Genomics revenue declined 5% in the quarter, while Sterilization and Disinfection Control revenue increased 18%. Biopharmaceutical Development revenue declined 9%, and Calibration Solutions revenue declined 7%.
Outlook, Commentary, Risks, and Unusual Items
- Customer Sema4 notified Mesa that it is exiting reproductive health screening and expects to significantly reduce future orders. Mesa reported approximately $8,200 of Sema4 revenue during the first twelve months of Agena ownership.
- Mesa initiated cost reductions in Clinical Genomics, including a reduction in force, expected to generate more than $4,000 in annualized savings. Management expects the Sema4 loss to materially reduce future Clinical Genomics revenue.
- Management noted supply-chain constraints, inflation affecting raw materials, labor and freight, and customer purchasing uncertainty. Calibration Solutions was particularly affected by raw-material shortages; management expects production difficulties to begin abating in the fourth quarter of fiscal 2023.
- China operations experienced COVID-related shutdowns and restrictions. Changes in Chinese COVID policies could affect future periods, although the filing states that the third quarter was not significantly affected.
- Foreign currency volatility reduced reported revenue and affected margins. Mesa does not hedge its foreign-exchange exposure.
- Mesa completed the $6,450 Belyntic acquisition during the quarter, adding peptide-purification consumables to Biopharmaceutical Development. The purchase price includes $1,500 payable if specified patents are issued, which management believes is probable within 36 months.
- In response to the loss of the significant customer, Mesa tested Clinical Genomics goodwill and intangible assets and concluded that no impairment was indicated as of December 31, 2022.
- Stock-based compensation was $9,859 year to date. A change in estimated performance-unit vesting produced a $1,427 pretax expense release in the quarter and is expected to reduce future non-cash stock compensation by approximately $392 per quarter.
- Management states that operating cash flow, cash on hand, Credit Facility capacity, and potential equity financing should be sufficient for ongoing operations, debt service, dividends, and anticipated capital expenditures. No specific revenue or earnings guidance was provided.
- The company declared a quarterly dividend of $0.16 per share payable March 15, 2023. Disclosure controls were deemed effective, and the filing reports no material changes to previously disclosed risk factors.
Investor Verification Checklist
- Verify the reporting-period discrepancy: the supplied filing is for December 31, 2022, not 2021 Q3.
- Assess the magnitude and duration of lost Sema4 revenue and whether Clinical Genomics cost reductions offset the decline.
- Monitor inventory growth, working-capital usage, operating cash flow, and the company’s ability to continue reducing Credit Facility borrowings.
- Review the sustainability of reported gross-margin improvement after excluding the prior-year Agena inventory step-up charge.
- Evaluate exposure to foreign exchange, inflation, supply constraints, China-related disruptions, and elevated interest rates.
- Review the $172,500 convertible notes due in 2025, including refinancing or share-settlement implications.
- Confirm the final purchase accounting for Belyntic and the potential $1,500 patent-contingent payment.
- Consider the unusually high year-to-date effective tax rate and the potential for future tax-rate volatility.